

Country	Year	Value	Unit
Algeria	1990	1.00	1000
Algeria	1991	1.00	1000
Algeria	1992	1.00	1000
Algeria	1993	1.00	1000
Algeria	1994	1.00	1000
Algeria	1995	1.00	1000
Algeria	1996	1.00	1000
Algeria	1997	1.00	1000
Algeria	1998	1.00	1000
Algeria	1999	1.00	1000
Algeria	2000	1.00	1000
Algeria	2001	1.00	1000
Algeria	2002	1.00	1000
Algeria	2003	1.00	1000
Algeria	2004	1.00	1000
Algeria	2005	1.00	1000
Algeria	2006	1.00	1000
Algeria	2007	1.00	1000
Algeria	2008	1.00	1000
Algeria	2009	1.00	1000
Algeria	2010	1.00	1000
Algeria	2011	1.00	1000
Algeria	2012	1.00	1000
Algeria	2013	1.00	1000
Algeria	2014	1.00	1000
Algeria	2015	1.00	1000
Algeria	2016	1.00	1000
Algeria	2017	1.00	1000
Algeria	2018	1.00	1000
Algeria	2019	1.00	1000
Algeria	2020	1.00	1000
Algeria	2021	1.00	1000
Algeria	2022	1.00	1000
Algeria	2023	1.00	1000
Algeria	2024	1.00	1000
Algeria	2025	1.00	1000
Algeria	2026	1.00	1000
Algeria	2027	1.00	1000
Algeria	2028	1.00	1000
Algeria	2029	1.00	1000
Algeria	2030	1.00	1000
Algeria	2031	1.00	1000
Algeria	2032	1.00	1000
Algeria	2033	1.00	1000
Algeria	2034	1.00	1000
Algeria	2035	1.00	1000
Algeria	2036	1.00	1000
Algeria	2037	1.00	1000
Algeria	2038	1.00	1000
Algeria	2039	1.00	1000
Algeria	2040	1.00	1000
Algeria	2041	1.00	1000
Algeria	2042	1.00	1000
Algeria	2043	1.00	1000
Algeria	2044	1.00	1000
Algeria	2045	1.00	1000
Algeria	2046	1.00	1000
Algeria	2047	1.00	1000
Algeria	2048	1.00	1000
Algeria	2049	1.00	1000
Algeria	2050	1.00	1000
Algeria	2051	1.00	1000
Algeria	2052	1.00	1000
Algeria	2053	1.00	1000
Algeria	2054	1.00	1000
Algeria	2055	1.00	1000
Algeria	2056	1.00	1000
Algeria	2057	1.00	1000
Algeria	2058	1.00	1000
Algeria	2059	1.00	1000
Algeria	2060	1.00	1000
Algeria	2061	1.00	1000
Algeria	2062	1.00	1000
Algeria	2063	1.00	1000
Algeria	2064	1.00	1000
Algeria	2065	1.00	1000
Algeria	2066	1.00	1000
Algeria	2067	1.00	1000
Algeria	2068	1.00	1000
Algeria	2069	1.00	1000
Algeria	2070	1.00	1000
Algeria	2071	1.00	1000
Algeria	2072	1.00	1000
Algeria	2073	1.00	1000
Algeria	2074	1.00	1000
Algeria	2075	1.00	1000
Algeria	2076	1.00	1000
Algeria	2077	1.00	1000

Attorney Docket No: 21486-032 DIV4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*

SERIAL NUMBER: To Be Assigned

EXAMINER: Not Yet Assigned

FILING DATE: July 11, 2001

ART UNIT: Not Yet Assigned

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

July 11, 2001

Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows.

In the specification:

On page 1, line 2, after the title, insert:

APPLICANTS: Wands et al.

FILED: Herewith

This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.

APPLICANTS: Wands et al.

FILED: Herewith

In the claims:

Cancel claims 1-25 and 28-38.

Add new claims 39-45.

0903199-07104

APPLICANTS: Wands et al.

FILED: Herewith

39. The method of claim 27, wherein said sequence comprises SEQ ID NO:4.
40. The method of claim 26, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
41. The method of claim 26, wherein said tumor is a cancer of the central nervous system.
42. The method of claim 26, wherein said tumor is a hepatocellular carcinoma.
43. The method of claim 26, wherein said tumor is a cholangiocarcinoma.
44. The method of claim 26, wherein said tumor is a glioblastoma.
45. The method of claim 26, wherein said tumor is a neuroblastoma.

109903199-071031

APPLICANTS: Wands et al.

FILED: Herewith

REMARKS

Claims 26-27, and 39-45 are pending, claims 1-25 and 28-38 having been canceled as being drawn to a non-elected invention. New claims 39-45 have been added. New claims 39 is supported by disclosure on page 7, line 49, to page 8, line 1, of the specification. New claims 40-41 page 1, lines 25-31, of the specification. New claims 42-43 are supported by disclosure on page 22, lines 5-6, of the specification. New claims 44-45 are supported by disclosure on page 17, line 29, and on page 42, lines 30-33, of the specification.

No new matter has been added by this amendment.

CONCLUSION

Applicants believe that the claims are in condition for allowance. The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 21486-032.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306

Attorney for Applicants

c/o MINTZ LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel.: (617) 542 6000

Fax: (617) 542-2241

TRADOCS:1540151

APPLICANTS: Wands et al.

FILED: Herewith

Appendix

In the specification:

On page 1, line 2, after the title, insert:

--This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.--

In the claims:

Cancel claims 1-25 and 28-38.

Add new claims 39-45.

APPLICANTS: Wands et al.

FILED: Herewith

--39. The method of claim 27, wherein said sequence comprises SEQ ID NO:4.--

--40. The method of claim 26, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.--

--41. The method of claim 26, wherein said tumor is a cancer of the central nervous system.--

--42. The method of claim 26, wherein said tumor is a hepatocellular carcinoma.--

--43. The method of claim 26, wherein said tumor is a cholangiocarcinoma.--

--44. The method of claim 26, wherein said tumor is a glioblastoma.--

--45. The method of claim 26, wherein said tumor is a cholangiocarcinoma.--

TRA 1540151v1